Patents Assigned to Secarna Pharmaceuticals GmbH & Co KG
  • Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39
    Patent number: 11959083
    Abstract: The present invention refers to immunosuppression-reverting oligonucleotides comprising 12 to 18 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of an ectonucleotidase (NTPdase; CD73) of SEQ ID NO.1 (human), wherein the oligonucleotide inhibits at least 50% of the CD39 expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: April 16, 2024
    Assignee: Secarna Pharmaceuticals GmbH & Co. KG
    Inventors: Frank Jaschinski, Tamara Thelemann
  • Oligonucleotide inhibiting the expression of Chop
    Patent number: 11781136
    Abstract: The present invention refers to an inhibitor consisting of oligonucleotides comprising 10 to 25 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of C/EBP-homologous protein (Chop) of SEQ ID NO.1 (human) and/or SEQ ID NO. 48 (human) but also with mouse and rat sequences, wherein the oligonucleotide N inhibits at least 50% of the Chop expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: October 10, 2023
    Assignee: Secarna Pharmaceuticals GmbH & Co. KG
    Inventors: Richard Klar, Frank Jaschinski, Sven Michel
  • Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancer
    Patent number: 11666595
    Abstract: The present invention relates to a novel approach for treating cancer, which is based on targeting PD-L1 mRNA. The invention is directed to oligonucleotides comprising 10 to 20 modified or unmodified nucleotides complementary to specifically selected regions of the PD-L1.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: June 6, 2023
    Assignee: Secarna Pharmaceuticals GmbH & Co. KG
    Inventors: Tamara Thelemann, Frank Jaschinski, Richard Klar
  • AGENT FOR THE PROPHYLAXIS AND THERAPY OF VIRAL INFECTION
    Publication number: 20180171339
    Abstract: The present invention relates to the preparation of a medicinal agent comprising DNAzymes according to Seq. ID 2-62 for the prophylaxis and treatment of virus infections that are caused by picornaviruses, in particular by rhinoviruses, in particular for the prophylaxis and treatment of rhinitis, head colds, asthma, COPD and viral infections of the upper respiratory tract.
    Type: Application
    Filed: May 13, 2016
    Publication date: June 21, 2018
    Applicant: Secarna Pharmaceuticals GmbH & Co KG
    Inventors: Daniel POTACZEK, Holger GARN, Harald RENZ